Stay updated on Tislelizumab & Sitravatinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Tislelizumab & Sitravatinib in NSCLC Clinical Trial page.

Latest updates to the Tislelizumab & Sitravatinib in NSCLC Clinical Trial page
- Check3 days agoChange DetectedA site-wide notice about government funding lapse and operating status was added, and the page revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check10 days agoChange DetectedThe history page now includes a glossary toggle and color-coded highlights to distinguish additions and deletions, improving readability of changes. It also displays revision notes (such as v3.4.0) and removes the previous No FEAR Act labeling.SummaryDifference0.8%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe update shows a small revision-history change, with Revision: v3.3.4 being added and Revision: v3.3.3 removed from the log. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check45 days agoChange DetectedRevision: v3.3.3 was added to the page history and HHS Vulnerability Disclosure and Revision: v3.3.2 were removed; these changes appear to be system/versioning and footer-level updates rather than alterations to study data or core page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check74 days agoChange DetectedA new revision entry 'Revision: v3.3.2' was added to the Record History, and the older 'Revision: v3.2.0' entry was removed.SummaryDifference0.1%

- Check81 days agoChange DetectedThe government funding lapse notice banner on the page was removed. The rest of the record history and trial details appear unchanged.SummaryDifference0.6%

Stay in the know with updates to Tislelizumab & Sitravatinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tislelizumab & Sitravatinib in NSCLC Clinical Trial page.